MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Acasti Pharma General and Administrative Expenses 2011-2026 | ACST
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.17 M | 6.68 M | 7.61 M | 9.26 M | 5.52 M | - | 4.24 M | 3.12 M | - | 1.61 M | 4.72 M | 6.03 M | 4.19 M | - | 858 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.26 M | 858 K | 5.08 M |
Quarterly General and Administrative Expenses Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.99 M | 1.96 M | 2.14 M | - | 1.51 M | 1.86 M | 2.26 M | - | 1.6 M | 1.63 M | 1.87 M | - | 1.59 M | 1.68 M | 1.92 M | - | 1.81 M | 7.44 M | 5.63 M | - | 1.1 M | 1.1 M | 1.32 M | 1.65 M | 1.58 M | 1.56 M | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.44 M | 1.1 M | 2.11 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
1.06 B | $ 7.71 | 1.65 % | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
28.1 M | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 221.52 | -0.16 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Heron Therapeutics
HRTX
|
54.6 M | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Immunovant
IMVT
|
77.2 M | $ 24.27 | 5.61 % | $ 3.68 B | USA |
 |
Incyte Corporation
INCY
|
1.38 B | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
369 K | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
9.62 M | $ 1.23 | 5.13 % | $ 22.1 M | USA |
 |
Inovio Pharmaceuticals
INO
|
47.6 M | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Innate Pharma S.A.
IPHA
|
25.5 M | $ 1.34 | 14.26 % | $ 235 M | France |
 |
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
27.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
128 M | - | -7.23 % | $ 13 M | USA |
 |
Inventiva S.A.
IVA
|
11.2 M | $ 6.09 | 5.36 % | $ 138 M | France |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
10.9 M | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
116 M | $ 16.93 | -0.41 % | $ 841 M | Britain |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
68.2 M | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
12.6 M | $ 8.33 | 0.97 % | $ 260 M | Israel |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |